Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...

Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

Zymeworks Inc. announced that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ZW171. This novel bispecific antibody targets ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based therapy for Hepatocellular carcinoma. RZ-001 employs advanced RNA editing to target and suppress cancer growth, showing ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...

Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking another major step in its $23 billion U.S. expansion plan. The site, the ...

Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...